Skip to main content

Caris Life Sciences signals beyond the news: 54+ signals from 5 sources

The latest Caris Life Sciences signal on this page is from Oct 27, 2026 (Patents): "Caris MPI, Inc.'s patent output is steady: 3 grants in the past year, 1 in the past 30 days." The busiest sources: Glassdoor (15+), LinkedIn (15+) and Website changes (15+).

Public (CAI)Biotechnology Research1,001 to 5,000 employeescarislifesciences.comLinkedIn

Get Caris Life Sciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Caris Life Sciences this week? Use Autobound signals for carislifesciences.com.
Signals
54+
Sources
5
Last 90 days
26
Latest
Oct 27, 2026

Source: Autobound Signal API · 71 signals tracked for Caris Life Sciences · updated

Other signals · latest 10

Latest Caris Life Sciences signals by source

54+ signals for Caris Life Sciences across 5 sources.

  1. Patents · Patent pace

    Caris MPI, Inc.'s patent output is steady: 3 grants in the past year, 1 in the past 30 days.

    Over the past year Caris MPI, Inc. received 3 US patent grants, concentrated in health tech / medical informatics and artificial intelligence / machine learning; the recent pace (2 in 90 days) is steady versus its trailing baseline.

    Grants, 12 months
    3
    Grants, 90 days
    2
    Grants, 30 days
    1
    USPTO assignee
    Caris MPI, Inc.

    Google Patents

  2. Glassdoor · PTO policy concerns

    Reviewers indicate need for more PTO and work life balance issues

    One employee explicitly mentions the need for more PTO and another reviewer gave a low rating for work-life balance despite the pros section mentioning it is a plus.

    Overall rating
    3.2 of 5
    CEO approval
    46%
    Reviews read
    2
    Review window
    Sep 16, 2026 to Oct 9, 2026

    Glassdoor

  3. Glassdoor · Consistent leadership complaints

    Employees report poor management and lack of direction

    Two employees describe management as needing better direction and one specifically states management needs to be replaced, indicating a significant leadership issue.

    Overall rating
    3.2 of 5
    CEO approval
    46%
    Reviews read
    2
    Review window
    Sep 16, 2026 to Oct 9, 2026

    Glassdoor

  4. Patents · Patent grant

    Caris MPI was granted a patent for molecular tumor profiling.

    In October 2026 Caris MPI patented cancer-testing methods that help identify potentially suitable treatments from tumor samples in clinical care and research.

    Patent title
    Molecular profiling of tumors
    Grant date
    Oct 6, 2026
    Inventors
    Daniel D. Von Hoff, David M. Loesch, Arlet Alarcon, Robert J. Penny

    Google Patents

  5. Website changes · Technical update

    Caris Life Sciences reported second-quarter 2026 financial results and increased 2026 revenue guidance, driven by strong performance in molecular profiling services.

    Added news item: “Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance,” stating that revenue growth was 45% driven by molecular profiling services, including approximately 59,200 clinical cases and over 114,000 whole exome/whole transcriptome tests.

    Page
    /news-and-events

    carislifesciences.com

  6. Website changes · Expansion general

    Caris reported growth in its precision-oncology ecosystem, with membership increasing from 95+ to 100+ worldwide and POA publications increasing from 1,050+ to 1,100+.

    Added: “100+ Members Worldwide” and “1,100+ POA Publications (abstracts, posters & manuscripts).”

    Page
    /

    carislifesciences.com

  7. LinkedIn

    Caris MI Clarity offers a prognostic test for early-stage breast cancer distant recurrence risk.

    Treatment decisions in early-stage breast cancer are often made without full visibility into late distant recurrence risk. Caris MI Clarity™ is a multimodal, computational pathology–based prognostic test that provides independent early (0–5 years) and late (5–15 years) distant recurrence risk from a single test at...

    Likes
    26
    Comments
    0
    Tags
    Medical Research, Healthcare Technology, Product Launch
    Initiatives
    providing independent early and late distant recurrence risk assessment

    LinkedIn

  8. LinkedIn

    Caris platform offers comprehensive tumor profiling using tissue and liquid biopsy for treatment decisions.

    Why choose between tissue and liquid biopsy when both could provide critical insights? The MI Cancer Seek® platform delivers comprehensive tumor profiling, including key mutations, fusions, protein expression, TMB, GPSai® and companion diagnostic indications. Caris Assure® adds a rapid, real-time view of...

    Likes
    74
    Comments
    0
    Tags
    Medical Research, Healthcare Technology, Product Development, Data Science
    Initiatives
    comprehensive tumor profiling for treatment guidance

    LinkedIn

  9. YouTube

    From the Human Genome Project to 48 Hours: The Rapid Evolution of Tumor Biology

    Video discusses rapid evolution of tumor biology diagnostics and the challenge of interpreting genetic data.

    Channel
    Association for Value-Based Cancer Care
    Views
    82
    Comments
    0
    Tags
    Precision Oncology, Tumor Biology, Genomics, Data Interpretation

    YouTube (Association for Value-Based Cancer Care)

  10. YouTube

    EP25 | 癌症刺客 Caris life sciences IPO

    Discussion on Caris Life Sciences, a Techbio company focused on precision oncology and cancer diagnostics.

    Views
    3
    Comments
    0
    Tags
    Precision Oncology, Diagnostics

    YouTube

Showing 10 of 54+ signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Caris Life Sciences with the Signal API

One POST /v1/companies/enrich call with carislifesciences.com returns Caris Life Sciences signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{
    "domain": "carislifesciences.com",
    "signal_types": ["reddit-company","podcast-company","glassdoor-company",
      "product-reviews","linkedin-post-company","twitter-company-posts",
      "youtube-company","website-intelligence","patents-company",
      "federal-contract-award","conference-speaker","hackernews",
      "producthunt-launch","seo-traffic"],
    "limit": 20
  }'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Company pages

Questions about Caris Life Sciences other signals

What signals does Autobound track for Caris Life Sciences besides news and filings?
This page lists 54+ signals for Caris Life Sciences from 5 sources: Glassdoor (15+), LinkedIn (15+), Website changes (15+), YouTube (7) and Patents (2). Every row is dated, and most link to the post, review or record.
What are people saying about Caris Life Sciences online?
The newest posts on this page: May 19, 2026, YouTube (YouTube (Association for Value-Based Cancer Care)): From the Human Genome Project to 48 Hours: The Rapid Evolution of Tumor Biology. May 8, 2026, YouTube: EP25 | 癌症刺客 Caris life sciences IPO. Apr 29, 2026, YouTube (YouTube (weldeiry)): Dr. Wafik El-Deiry’s Remarks at Inaugural Caris POA Member Meeting, Brown University April 28, 2026.
What do employees say about working at Caris Life Sciences?
The newest Glassdoor theme on this page, dated Oct 9, 2026: Reviewers indicate need for more PTO and work life balance issues. The overall rating in that row is 3.2 of 5. Themes summarize recent reviews; read the reviews on Glassdoor for the full picture.
Has Caris Life Sciences been granted patents recently?
Yes. The newest grant on this page: Oct 6, 2026, Patents (Google Patents): Caris MPI was granted a patent for molecular tumor profiling.

Page updated , the date of the newest row on this page.

Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.

Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.

Data as of .

How this data is built →Get it from the Signal API →